Browse studies

Find your next paid study

18 recruiting studies matching your filters

Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors

The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malign…

NeuroblastomaPheochromocytoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT00107289

Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAP…

SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)Mesothelioma+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06503146

Phase 1

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more

Estimated

~$10 – $8,750

Perspective TherapeuticsNCT05636618

Phase 1

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Pheochromocytoma and Paraganglioma

This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment. A pre-treatment 1…

PheochromocytomaParaganglioma

Estimated

~$10 – $7,500

Heather WachtelNCT05636540

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic scre…

PheochromocytomaParagangliomaInherited Cancer Syndrome+5 more

Estimated

~$10 – $750

The University of Texas Health Science Center at San AntonioNCT03160274

Phase 1

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

Estimated

~$10 – $7,500

Anusha Kalbasi